DiaMedica Therapeutics Inc. Financing Cash Flow
DiaMedica Therapeutics Inc. (DMAC) reported Financing Cash Flow of $549.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $132.00K, a 18.01% decline year-over-year.
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $417.00K, a 358.24% increase year-over-year.
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $12.09M, a 9975.83% increase year-over-year.
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $31.53M, a 25536.59% increase year-over-year.
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $43.88M, a 265.82% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $11.99M, a 67.44% decline from fiscal 2023.
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $36.84M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$6.00K, a 100.02% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $549.00K 10-Q · filed 2026-08-10 | $12.64M derived: sum of 3 quarters · filed 2026-08-10 | $44.17M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $417.00K 10-Q · filed 2026-05-06 | $12.51M derived: sum of 2 quarters · filed 2026-05-06 | $44.04M derived: sum of 3 quarters · filed 2026-05-06 | $44.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $43.62M derived: sum of 2 quarters · filed 2026-03-30 | $43.78M derived: sum of 3 quarters · filed 2026-08-10 | $43.88M 10-K · filed 2026-03-30 |
| 2025-09-30 | $31.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $31.69M derived: sum of 2 quarters · filed 2026-08-10 | $31.79M 10-Q · filed 2025-11-12 | $31.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $252.00K 10-Q · filed 2026-08-10 | $372.00K derived: sum of 3 quarters · filed 2026-08-10 | $495.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $91.00K 10-Q · filed 2026-05-06 | $211.00K derived: sum of 2 quarters · filed 2026-05-06 | $334.00K derived: sum of 3 quarters · filed 2026-05-06 | $12.09M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $243.00K derived: sum of 2 quarters · filed 2026-03-30 | $11.99M derived: sum of 3 quarters · filed 2026-03-30 | $11.99M 10-K · filed 2026-03-30 |
| 2024-09-30 | $123.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $11.88M derived: sum of 2 quarters · filed 2025-11-12 | $11.87M 10-Q · filed 2025-11-12 | $11.87M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $11.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $11.75M 10-Q · filed 2025-08-12 | $11.75M derived: sum of 3 quarters · filed 2025-08-12 | $11.74M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.00K 10-Q · filed 2025-05-13 | -$2.00K derived: sum of 2 quarters · filed 2025-05-13 | -$8.00K derived: sum of 3 quarters · filed 2025-05-13 | $36.84M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$7.00K derived: sum of 2 quarters · filed 2025-03-17 | $36.84M derived: sum of 3 quarters · filed 2025-03-17 | $36.84M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $36.84M derived: sum of 2 quarters · filed 2024-11-13 | $36.84M 10-Q · filed 2024-11-13 | $36.84M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $36.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $36.85M 10-Q · filed 2024-08-07 | $36.85M derived: sum of 3 quarters · filed 2024-08-07 | $36.85M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$1.00K 10-Q · filed 2024-05-08 | -$2.00K derived: sum of 2 quarters · filed 2024-05-08 | -$4.00K derived: sum of 3 quarters · filed 2024-05-08 | -$6.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$3.00K derived: sum of 2 quarters · filed 2024-03-19 | -$5.00K derived: sum of 3 quarters · filed 2024-03-19 | -$6.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$4.00K derived: sum of 2 quarters · filed 2023-11-13 | -$5.00K 10-Q · filed 2023-11-13 | -$24.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$3.00K 10-Q · filed 2023-08-14 | -$22.00K derived: sum of 3 quarters · filed 2023-08-14 | $29.84M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$1.00K 10-Q · filed 2023-05-15 | -$20.00K derived: sum of 2 quarters · filed 2023-05-15 | $29.84M derived: sum of 3 quarters · filed 2023-05-15 | $29.84M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $29.85M derived: sum of 2 quarters · filed 2023-03-28 | $29.84M derived: sum of 3 quarters · filed 2023-03-28 | $30.09M 10-K · filed 2023-03-28 |
| 2021-09-30 | $29.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $29.86M derived: sum of 2 quarters · filed 2022-11-09 | $30.11M 10-Q · filed 2022-11-09 | $30.07M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $241.00K 10-Q · filed 2022-08-11 | $202.00K derived: sum of 3 quarters · filed 2022-08-11 | $21.39M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $242.00K 10-Q · filed 2022-05-04 | $203.00K derived: sum of 2 quarters · filed 2022-05-04 | $21.39M derived: sum of 3 quarters · filed 2022-05-04 | $21.39M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $21.15M derived: sum of 2 quarters · filed 2022-03-14 | $21.15M derived: sum of 3 quarters · filed 2022-03-14 | $28.84M 10-K · filed 2022-03-14 |
| 2020-09-30 | $21.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $21.19M derived: sum of 2 quarters · filed 2021-11-10 | $28.88M 10-Q · filed 2021-11-10 | $28.88M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $7.70M 10-Q · filed 2021-08-11 | $7.69M derived: sum of 3 quarters · filed 2021-08-11 | $7.69M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $7.70M 10-Q · filed 2021-05-05 | $7.70M derived: sum of 2 quarters · filed 2021-05-05 | $7.69M derived: sum of 3 quarters · filed 2021-05-05 | $7.77M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$2.00K derived: sum of 2 quarters · filed 2021-03-10 | $72.00K derived: sum of 3 quarters · filed 2021-03-10 | $70.00K 10-K · filed 2021-03-10 |
| 2019-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $73.00K derived: sum of 2 quarters · filed 2020-11-04 | $71.00K 10-Q · filed 2020-11-04 | $14.88M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $72.00K 10-Q · filed 2020-08-11 | $14.88M derived: sum of 3 quarters · filed 2020-08-11 | $14.91M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$2.00K 10-Q · filed 2020-05-13 | $14.81M derived: sum of 2 quarters · filed 2020-05-13 | $14.84M derived: sum of 3 quarters · filed 2020-05-13 | $14.89M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $14.81M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $14.84M derived: sum of 2 quarters · filed 2020-03-23 | $14.89M derived: sum of 3 quarters · filed 2020-03-23 | $21.22M 10-K · filed 2020-03-23 |
| 2018-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $80.00K derived: sum of 2 quarters · filed 2019-11-13 | $6.40M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $6.37M 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | $6.32M 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | $3.54M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |